What will happen to the Sigma share price after the Chemist Warehouse merger?

Morgan Stanley analysts explain the default factor that will support the Sigma share price after the merger.

| More on:
The last piece of the jigsaw being fitted, indicating good news for a share price on merger or acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Sigma Healthcare Ltd (ASX: SIG) share price is trading at $2.89 on Thursday, up 1.05%.

The company was the No. 1 stock for price growth among ASX 200 healthcare shares in 2024.

The Sigma share price ripped 162% higher to close at $2.62 on 31 December. By comparison, the S&P/ASX 200 Index (ASX: XJO) rose by 7.49%, and the S&P/ASX 200 Health Care Index (ASX: XHJ) lifted by 6.01%.

Sigma owns a network of chemists, including Amcal, Discount Drug Stores, and Guardian Pharmacy. Its big price surge last year was due to excitement over its proposed mega-merger with the privately owned Chemist Warehouse pharmaceutical chain.

Sigma shares had a market capitalisation of $800 million at the time of the merger announcement on 11 December 2023. Astounding share price growth has increased that market cap to $4.66 billion today.

Sigma hopes that the merger will be finalised early next month.

What will happen to the Sigma share price?

Morgan Stanley analysts say the merged company, which will be much larger than Sigma is today, will benefit enormously from passive index investors once it begins trading.

According to the Australian Financial Review (AFR), Morgan Stanley analysts estimate that Sigma's share weight in the S&P/ASX 200 Index (ASX: XJO) could climb 50 basis points after the merger. This would generate $537 million worth of trades from ASX 200 index funds and exchange-traded funds (ETFs).

Passive investing through ETFs is rising in popularity. According to ETF provider BetaShares, almost $250 billion is invested in almost 400 ETFs listed on the ASX and CBOE.

The biggest ETF on the market, worth $17.69 billion, is the Vanguard Australian Shares Index ETF (ASX: VAS), which tracks the performance of the S&P/ASX 300 Index (ASX: XKO). There are also several ETFs that track the benchmark ASX 200.

Passive investing is the default factor that will immediately support the Sigma share price post-merger.

This is because most ETFs track market cap-weighted indexes, which means they buy more shares in larger companies by default.

Morgan Stanley equity strategist Antony Conte explains:

We estimate the additional size would drive significant passive demand.

We will also likely observe subsequent flow across existing members, namely across the larger members as the index weights recalibrate to account for Sigma's additional size.

What's next?

The Australian Competition & Consumer Commission (ACCC) green-lighted the merger in November.

The next step is a Sigma shareholders vote on 29 January, after which Chemist Warehouse shareholders will need to approve the scheme of arrangement. Then it's a matter of waiting for final court approval and sign-off.

The indicative date for implementation of the transaction is 12 February.

The Sigma board has unanimously recommended the deal to shareholders.

In Sigma's notice of the meeting to vote, chair Michael Sammells said:

This transformational opportunity will bring together two highly complementary businesses including Australia's leading retail pharmacy franchisor and a dynamic and efficient pharmaceutical wholesale operation.

Should you invest $1,000 in Sigma Healthcare right now?

Before you buy Sigma Healthcare shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Sigma Healthcare wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 9 January 2025

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three health professionals at a hospital smile for the camera.
Healthcare Shares

3 ASX healthcare stocks soaring on positive company updates

These companies have exciting news for investors today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Guess which ASX 200 biotech stock is jumping 15% on big US FDA news

Why is this stock ending the week on a high? Let's see what is getting investors excited.

Read more »

A man in his 30s with a clipped beard sits at his laptop on a desk with one finger to the side of his face and his chin resting on his thumb as he looks concerned while staring at his computer screen.
Healthcare Shares

The CSL share price is down 14% from its 52-week high. Is it a buy?

Let's see if analysts think that investors should be snapping up this quality company's shares.

Read more »

A young woman with her mouth open and her hands out showing surprise and delight as uranium share prices skyrocket
Healthcare Shares

Guess which ASX 300 stock is jumping amid huge profit growth

The company is forecasting its profits to more than double in the first half.

Read more »

A group of businesspeople clapping.
Healthcare Shares

This fund returned 109% in 2024. Here are 2 of its best-performing ASX shares

Small caps proved to be the winners last year.

Read more »

Lines of codes and graphs in the background with woman looking at laptop trying to understand the data.
Healthcare Shares

Up 175% in a year, is this why the Sigma share price is falling this week?

Sigma shares are taking a tumble again today. But why?

Read more »

Healthcare Shares

Up 19% in a month, what's driving Mesoblast shares?

Investors have piled into the stock en masse this past month.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Healthcare Shares

Mesoblast shares dip then flip on $800,000 insider buy

The Mesoblast share price is resettling after a near-70% spike in December.

Read more »